Tags

Type your tag names separated by a space and hit enter

Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
Exp Oncol. 2009 Mar; 31(1):48-51.EO

Abstract

AIM

To study the expression of estrogen receptors (ER) and progesterone receptors (PR) and proliferation marker Ki-67 in ovarian tumors using immunohistochemistry, and evaluate possible prognostic significance of these markers.

METHODS

Immunohistochemical evaluation of Ki-67, ER and PR expression was performed on serous ovarian cancer (OC) tissue samples from 81 OC patients.

RESULTS

Serous OC is characterised by high proliferative activity and increased expression of steroid hormone receptors compared to nontransfomed ovarian surface epithelium. It has been shown that ER and PR expression levels depend on tumor histologic grade and the stage of the disease, and are variable between tumors of the same grade. The ER and PR expression levels correlate with OC patients' survival.

CONCLUSION

Proliferative activity and steroid hormone receptor status along with clinical and morphological characteristics of serous OC possess prognostic significance and may be used for evaluation of the disease course.

Authors+Show Affiliations

R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine. lubov@onconet.kiev.uaNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19300417

Citation

Buchynska, L G., et al. "Expression of the Estrogen and Progesterone Receptors as Prognostic Factor in Serous Ovarian Cancers." Experimental Oncology, vol. 31, no. 1, 2009, pp. 48-51.
Buchynska LG, Iurchenko NP, Grinkevych VM, et al. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol. 2009;31(1):48-51.
Buchynska, L. G., Iurchenko, N. P., Grinkevych, V. M., Nesina, I. P., Chekhun, S. V., & Svintsitsky, V. S. (2009). Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Experimental Oncology, 31(1), 48-51.
Buchynska LG, et al. Expression of the Estrogen and Progesterone Receptors as Prognostic Factor in Serous Ovarian Cancers. Exp Oncol. 2009;31(1):48-51. PubMed PMID: 19300417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. AU - Buchynska,L G, AU - Iurchenko,N P, AU - Grinkevych,V M, AU - Nesina,I P, AU - Chekhun,S V, AU - Svintsitsky,V S, PY - 2009/3/21/entrez PY - 2009/3/21/pubmed PY - 2009/5/19/medline SP - 48 EP - 51 JF - Experimental oncology JO - Exp Oncol VL - 31 IS - 1 N2 - AIM: To study the expression of estrogen receptors (ER) and progesterone receptors (PR) and proliferation marker Ki-67 in ovarian tumors using immunohistochemistry, and evaluate possible prognostic significance of these markers. METHODS: Immunohistochemical evaluation of Ki-67, ER and PR expression was performed on serous ovarian cancer (OC) tissue samples from 81 OC patients. RESULTS: Serous OC is characterised by high proliferative activity and increased expression of steroid hormone receptors compared to nontransfomed ovarian surface epithelium. It has been shown that ER and PR expression levels depend on tumor histologic grade and the stage of the disease, and are variable between tumors of the same grade. The ER and PR expression levels correlate with OC patients' survival. CONCLUSION: Proliferative activity and steroid hormone receptor status along with clinical and morphological characteristics of serous OC possess prognostic significance and may be used for evaluation of the disease course. SN - 1812-9269 UR - https://www.unboundmedicine.com/medline/citation/19300417/Expression_of_the_estrogen_and_progesterone_receptors_as_prognostic_factor_in_serous_ovarian_cancers_ L2 - https://medlineplus.gov/ovariancancer.html DB - PRIME DP - Unbound Medicine ER -